{"filing":{"accession_number":"0001725160-26-000045","cik":"0001725160","ticker":"ZNTL","company_name":"Zentalis Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"zntl-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000045/zntl-20260521.htm"},"events":[{"id":9604,"run_id":8424,"accession_number":"0001725160-26-000045","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Zentalis announced Phase 1b clinical trial data for azenosertib in combination with paclitaxel in platinum-resistant ovarian cancer patients, demonstrating an ORR of 39.1% and median PFS of 7.3 months with a manageable safety profile. This represents a significant clinical milestone for the company's lead drug candidate.","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1274,"accession_number":"0001725160-26-000045","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.65,"reasoning":"The filing discloses a press release under Item 7.01 (Regulation FD Disclosure) but provides no substantive content about what the press release contains. Without access to Exhibit 99.1, the materiality and specific event type cannot be determined. The boilerplate language about non-filing status suggests this is a routine disclosure, but the actual event remains unknown. Classification defaults to \"other_material\" with low confidence pending review of the actual press release content.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:22:18.950459+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1275,"accession_number":"0001725160-26-000045","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Zentalis announced Phase 1b clinical trial data for azenosertib in combination with paclitaxel in platinum-resistant ovarian cancer patients, showing an ORR of 39.1% and median PFS of 7.3 months with a manageable safety profile. While this is a significant clinical milestone for a development-stage biopharmaceutical company whose viability depends substantially on azenosertib's success, it does not fit neatly into the standard 8-K event taxonomy (not an earnings release, M\u0026A activity, restatement, or other specifically enumerated event). The disclosure is material to investors assessing the company's pipeline progress and drug candidate potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:22:18.950459+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1274,"accession_number":"0001725160-26-000045","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.65,"reasoning":"The filing discloses a press release under Item 7.01 (Regulation FD Disclosure) but provides no substantive content about what the press release contains. Without access to Exhibit 99.1, the materiality and specific event type cannot be determined. The boilerplate language about non-filing status suggests this is a routine disclosure, but the actual event remains unknown. Classification defaults to \"other_material\" with low confidence pending review of the actual press release content.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:22:18.950459+00:00","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-05-21"},{"id":1275,"accession_number":"0001725160-26-000045","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Zentalis announced Phase 1b clinical trial data for azenosertib in combination with paclitaxel in platinum-resistant ovarian cancer patients, showing an ORR of 39.1% and median PFS of 7.3 months with a manageable safety profile. While this is a significant clinical milestone for a development-stage biopharmaceutical company whose viability depends substantially on azenosertib's success, it does not fit neatly into the standard 8-K event taxonomy (not an earnings release, M\u0026A activity, restatement, or other specifically enumerated event). The disclosure is material to investors assessing the company's pipeline progress and drug candidate potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:22:18.950459+00:00","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-05-21"}]}